Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits?
Goals of the study included evaluating the long-term efficacy of rivastigmine in Alzheimer's disease (AD) patient categories stratified by baseline dementia severity, and post hoc investigation of particular benefits of early initiation of rivastigmine treatment in moderately severe AD. Both ri...
Gespeichert in:
| Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 2002-05, Vol.26 (4), p.705-712 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 712 |
|---|---|
| container_issue | 4 |
| container_start_page | 705 |
| container_title | Progress in neuro-psychopharmacology & biological psychiatry |
| container_volume | 26 |
| creator | Doraiswamy, P.Murali Krishnan, K.Ranga Rama Anand, Ravi Sohn, Hyesung Danyluk, Jacquiline Hartman, Richard D. Veach, Jeffrey |
| description | Goals of the study included evaluating the long-term efficacy of rivastigmine in Alzheimer's disease (AD) patient categories stratified by baseline dementia severity, and post hoc investigation of particular benefits of early initiation of rivastigmine treatment in moderately severe AD. Both rivastigmine-treated groups (originally randomized to 1–4 or 6–12 mg/day) experienced significantly smaller declines in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores from baseline than the projected placebo group after 52 weeks. Patients receiving rivastigmine from Day 1 experienced significantly less decline compared with patients originally receiving placebo and then initiating rivastigmine treatment after a 6-month delay. Furthermore, cognitive benefits were more robust in patients with moderately severe disease compared with previous reports in mild to moderately severe AD. Findings suggest that early treatment with rivastigmine 6–12 mg/day is associated with sustained long-term cognitive benefits in patients with moderately severe AD. The results support the value of early treatment of AD patients, particularly those with moderately severe AD. |
| doi_str_mv | 10.1016/S0278-5846(01)00326-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72021288</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0278584601003268</els_id><sourcerecordid>72021288</sourcerecordid><originalsourceid>FETCH-LOGICAL-e293t-7a781cbf915b7cf26f3a9b88a2e07adfc85a901aaa25128a73567c59237fe9673</originalsourceid><addsrcrecordid>eNpFkctuFDEQRS0EIkPgE0De8Fo0-JFuu9lEUXhKI7EA1la1u5wYdbsnLs9Iwwfw3XiSAVZVKp26pbqXsadSvJFCdm-_CWVs09qz7pWQr4XQqmvsPbaSto7PlOzus9U_5IQ9IvophJBa6IfsRCpprRR6xX6vl3TVFMwzxxDQF-JL4DnugEq8mmNCHhOflxEzFJz2nHCHGfnF9Osa44z5JfExEgLhO_5-QeIIuWIxxRKhxCUd9Mp1Xd_saxswc9pSgao88gEThljo_DF7EGAifHKsp-zHxw_fLz8366-fvlxerBtUvS6NAWOlH0Iv28H4oLqgoR-sBYXCwBi8baEXEgBUK5UFo9vO-LZX2gTsO6NP2Ys73U1ebrZIxc2RPE4TJFy25IwSqi7aCj47gtthxtFtcpwh791f5yrw_AgAeZhChuQj_ee0rW63h4vndxzWt3YRsyMfMXkcY652u3GJTgp3yNTdZuoOgTkh3W2mzuo_YziUdA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72021288</pqid></control><display><type>article</type><title>Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Doraiswamy, P.Murali ; Krishnan, K.Ranga Rama ; Anand, Ravi ; Sohn, Hyesung ; Danyluk, Jacquiline ; Hartman, Richard D. ; Veach, Jeffrey</creator><creatorcontrib>Doraiswamy, P.Murali ; Krishnan, K.Ranga Rama ; Anand, Ravi ; Sohn, Hyesung ; Danyluk, Jacquiline ; Hartman, Richard D. ; Veach, Jeffrey</creatorcontrib><description>Goals of the study included evaluating the long-term efficacy of rivastigmine in Alzheimer's disease (AD) patient categories stratified by baseline dementia severity, and post hoc investigation of particular benefits of early initiation of rivastigmine treatment in moderately severe AD. Both rivastigmine-treated groups (originally randomized to 1–4 or 6–12 mg/day) experienced significantly smaller declines in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores from baseline than the projected placebo group after 52 weeks. Patients receiving rivastigmine from Day 1 experienced significantly less decline compared with patients originally receiving placebo and then initiating rivastigmine treatment after a 6-month delay. Furthermore, cognitive benefits were more robust in patients with moderately severe disease compared with previous reports in mild to moderately severe AD. Findings suggest that early treatment with rivastigmine 6–12 mg/day is associated with sustained long-term cognitive benefits in patients with moderately severe AD. The results support the value of early treatment of AD patients, particularly those with moderately severe AD.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/S0278-5846(01)00326-8</identifier><identifier>PMID: 12188103</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - drug therapy ; Alzheimer Disease - psychology ; Alzheimer's disease ; Analysis of Variance ; Biological and medical sciences ; Carbamates - administration & dosage ; Carbamates - therapeutic use ; Cholinesterase inhibitor ; Double-Blind Method ; Efficacy ; Female ; Humans ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Phenylcarbamates ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Rivastigmine ; Time</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 2002-05, Vol.26 (4), p.705-712</ispartof><rights>2002 Elsevier Science Inc.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0278584601003268$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13800157$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12188103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Doraiswamy, P.Murali</creatorcontrib><creatorcontrib>Krishnan, K.Ranga Rama</creatorcontrib><creatorcontrib>Anand, Ravi</creatorcontrib><creatorcontrib>Sohn, Hyesung</creatorcontrib><creatorcontrib>Danyluk, Jacquiline</creatorcontrib><creatorcontrib>Hartman, Richard D.</creatorcontrib><creatorcontrib>Veach, Jeffrey</creatorcontrib><title>Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits?</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Goals of the study included evaluating the long-term efficacy of rivastigmine in Alzheimer's disease (AD) patient categories stratified by baseline dementia severity, and post hoc investigation of particular benefits of early initiation of rivastigmine treatment in moderately severe AD. Both rivastigmine-treated groups (originally randomized to 1–4 or 6–12 mg/day) experienced significantly smaller declines in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores from baseline than the projected placebo group after 52 weeks. Patients receiving rivastigmine from Day 1 experienced significantly less decline compared with patients originally receiving placebo and then initiating rivastigmine treatment after a 6-month delay. Furthermore, cognitive benefits were more robust in patients with moderately severe disease compared with previous reports in mild to moderately severe AD. Findings suggest that early treatment with rivastigmine 6–12 mg/day is associated with sustained long-term cognitive benefits in patients with moderately severe AD. The results support the value of early treatment of AD patients, particularly those with moderately severe AD.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - psychology</subject><subject>Alzheimer's disease</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Carbamates - administration & dosage</subject><subject>Carbamates - therapeutic use</subject><subject>Cholinesterase inhibitor</subject><subject>Double-Blind Method</subject><subject>Efficacy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenylcarbamates</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rivastigmine</subject><subject>Time</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkctuFDEQRS0EIkPgE0De8Fo0-JFuu9lEUXhKI7EA1la1u5wYdbsnLs9Iwwfw3XiSAVZVKp26pbqXsadSvJFCdm-_CWVs09qz7pWQr4XQqmvsPbaSto7PlOzus9U_5IQ9IvophJBa6IfsRCpprRR6xX6vl3TVFMwzxxDQF-JL4DnugEq8mmNCHhOflxEzFJz2nHCHGfnF9Osa44z5JfExEgLhO_5-QeIIuWIxxRKhxCUd9Mp1Xd_saxswc9pSgao88gEThljo_DF7EGAifHKsp-zHxw_fLz8366-fvlxerBtUvS6NAWOlH0Iv28H4oLqgoR-sBYXCwBi8baEXEgBUK5UFo9vO-LZX2gTsO6NP2Ys73U1ebrZIxc2RPE4TJFy25IwSqi7aCj47gtthxtFtcpwh791f5yrw_AgAeZhChuQj_ee0rW63h4vndxzWt3YRsyMfMXkcY652u3GJTgp3yNTdZuoOgTkh3W2mzuo_YziUdA</recordid><startdate>20020501</startdate><enddate>20020501</enddate><creator>Doraiswamy, P.Murali</creator><creator>Krishnan, K.Ranga Rama</creator><creator>Anand, Ravi</creator><creator>Sohn, Hyesung</creator><creator>Danyluk, Jacquiline</creator><creator>Hartman, Richard D.</creator><creator>Veach, Jeffrey</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20020501</creationdate><title>Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits?</title><author>Doraiswamy, P.Murali ; Krishnan, K.Ranga Rama ; Anand, Ravi ; Sohn, Hyesung ; Danyluk, Jacquiline ; Hartman, Richard D. ; Veach, Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e293t-7a781cbf915b7cf26f3a9b88a2e07adfc85a901aaa25128a73567c59237fe9673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - psychology</topic><topic>Alzheimer's disease</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Carbamates - administration & dosage</topic><topic>Carbamates - therapeutic use</topic><topic>Cholinesterase inhibitor</topic><topic>Double-Blind Method</topic><topic>Efficacy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenylcarbamates</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rivastigmine</topic><topic>Time</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Doraiswamy, P.Murali</creatorcontrib><creatorcontrib>Krishnan, K.Ranga Rama</creatorcontrib><creatorcontrib>Anand, Ravi</creatorcontrib><creatorcontrib>Sohn, Hyesung</creatorcontrib><creatorcontrib>Danyluk, Jacquiline</creatorcontrib><creatorcontrib>Hartman, Richard D.</creatorcontrib><creatorcontrib>Veach, Jeffrey</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Doraiswamy, P.Murali</au><au>Krishnan, K.Ranga Rama</au><au>Anand, Ravi</au><au>Sohn, Hyesung</au><au>Danyluk, Jacquiline</au><au>Hartman, Richard D.</au><au>Veach, Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits?</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>2002-05-01</date><risdate>2002</risdate><volume>26</volume><issue>4</issue><spage>705</spage><epage>712</epage><pages>705-712</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>Goals of the study included evaluating the long-term efficacy of rivastigmine in Alzheimer's disease (AD) patient categories stratified by baseline dementia severity, and post hoc investigation of particular benefits of early initiation of rivastigmine treatment in moderately severe AD. Both rivastigmine-treated groups (originally randomized to 1–4 or 6–12 mg/day) experienced significantly smaller declines in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores from baseline than the projected placebo group after 52 weeks. Patients receiving rivastigmine from Day 1 experienced significantly less decline compared with patients originally receiving placebo and then initiating rivastigmine treatment after a 6-month delay. Furthermore, cognitive benefits were more robust in patients with moderately severe disease compared with previous reports in mild to moderately severe AD. Findings suggest that early treatment with rivastigmine 6–12 mg/day is associated with sustained long-term cognitive benefits in patients with moderately severe AD. The results support the value of early treatment of AD patients, particularly those with moderately severe AD.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>12188103</pmid><doi>10.1016/S0278-5846(01)00326-8</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-5846 |
| ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 2002-05, Vol.26 (4), p.705-712 |
| issn | 0278-5846 1878-4216 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72021288 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Aged, 80 and over Alzheimer Disease - drug therapy Alzheimer Disease - psychology Alzheimer's disease Analysis of Variance Biological and medical sciences Carbamates - administration & dosage Carbamates - therapeutic use Cholinesterase inhibitor Double-Blind Method Efficacy Female Humans Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Phenylcarbamates Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Rivastigmine Time |
| title | Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A57%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20effects%20of%20rivastigmine%20in%20moderately%20severe%20Alzheimer's%20disease:%20Does%20early%20initiation%20of%20therapy%20offer%20sustained%20benefits?&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Doraiswamy,%20P.Murali&rft.date=2002-05-01&rft.volume=26&rft.issue=4&rft.spage=705&rft.epage=712&rft.pages=705-712&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/S0278-5846(01)00326-8&rft_dat=%3Cproquest_pubme%3E72021288%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72021288&rft_id=info:pmid/12188103&rft_els_id=S0278584601003268&rfr_iscdi=true |